- Home
- RYTM vs TMDX Comparison
RYTM vs TMDX Comparison
Compare RYTM & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- TMDX
- Stock Information
- Founded
- RYTM 2008
- TMDX 1998
- Country
- RYTM United States
- TMDX United States
- Employees
- RYTM N/A
- TMDX N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RYTM Health Care
- TMDX Health Care
- Exchange
- RYTM Nasdaq
- TMDX Nasdaq
- Market Cap
- RYTM 5.9B
- TMDX 4.8B
- IPO Year
- RYTM 2017
- TMDX 2019
- Fundamental
- Price
- RYTM $88.64
- TMDX $110.69
- Analyst Decision
- RYTM Strong Buy
- TMDX Buy
- Analyst Count
- RYTM 13
- TMDX 9
- Target Price
- RYTM $89.77
- TMDX $129.88
- AVG Volume (30 Days)
- RYTM 1.0M
- TMDX 902.5K
- Earning Date
- RYTM 08-05-2025
- TMDX 07-30-2025
- Dividend Yield
- RYTM N/A
- TMDX N/A
- EPS Growth
- RYTM N/A
- TMDX N/A
- EPS
- RYTM N/A
- TMDX 1.41
- Revenue
- RYTM $136,863,000.00
- TMDX $488,227,000.00
- Revenue This Year
- RYTM $37.47
- TMDX $34.07
- Revenue Next Year
- RYTM $71.16
- TMDX $20.76
- P/E Ratio
- RYTM N/A
- TMDX $74.96
- Revenue Growth
- RYTM 48.88
- TMDX 64.43
- 52 Week Low
- RYTM $40.61
- TMDX $55.00
- 52 Week High
- RYTM $94.80
- TMDX $177.37
- Technical
- Relative Strength Index (RSI)
- RYTM 71.18
- TMDX 35.52
- Support Level
- RYTM $87.86
- TMDX $98.89
- Resistance Level
- RYTM $92.14
- TMDX $120.45
- Average True Range (ATR)
- RYTM 3.57
- TMDX 5.69
- MACD
- RYTM 1.01
- TMDX -2.08
- Stochastic Oscillator
- RYTM 77.38
- TMDX 29.14
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.